Blog
RSS FeedPosted by Michael Wonder on 03 Mar 2021
Paying for prescription drugs in the new administration
2 March 2021 - In a national survey in January 2020 involving 1011 participants, the second-ranked domestic priority for members of ...
Posted by Michael Wonder on 24 Feb 2021
Bladder cancer drug shortage resolved with Health Canada approval
24 February 2021 - Verity-BCG bladder cancer treatment available for Canadian patients in the spring. ...
Posted by Michael Wonder on 24 Feb 2021
TGA reviewing COVID-19 tests to rule out issues diagnosing variants
24 February 2021 - Adjunct Professor John Skerritt has tasked the nation’s medical regulator with ensuring COVID-19 tests are successfully ...
Posted by Michael Wonder on 24 Feb 2021
Tecartus recommended by NICE
24 February 2021 - Treatment with autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel) is recommended for use within the Cancer Drugs Fund ...
Posted by Michael Wonder on 24 Feb 2021
NICE terminates appraisal of Novartis medicine
24 February 2021 - NICE had intended to appraise omalizumab for the treatment of patients with chronic rhinosinusitis with nasal ...
Posted by Michael Wonder on 24 Feb 2021
Takeda’s drug for acute hereditary angioedema seizure to get larger benefits
24 February 2021 - Takeda Pharmaceutical Korea said that the Ministry of Health and Welfare would grant expanded reimbursement for ...
Posted by Michael Wonder on 24 Feb 2021
Anti-cancer drugs Ninlaro, Lutathera to get insurance benefits from March
24 February 2021 - Takeda’s multiple myeloma treatment Ninlaro (ixazomib) and Novartis’ neuroendocrine tumour drug Lutathera (lutetium oxodotreotide) will get ...
Posted by Michael Wonder on 24 Feb 2021
ViiV Healthcare submits supplemental new drug application to US FDA for expanded use of Cabenuva (cabotegravir, rilpivirine) as an HIV treatment for use every 2 months
24 February 2021 - ViiV Healthcare announced today the submission of a supplemental new drug application to the US FDA for ...
Posted by Michael Wonder on 24 Feb 2021
Locate Bio’s Chondro3 granted FDA breakthrough device designation
24 February 2021 - The Company’s second FDA Breakthrough Device designation granted in 2021. ...
Posted by Michael Wonder on 24 Feb 2021
EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19
24 February 2021 - EMA’s CHMP has started a ‘rolling review’ of data on the monoclonal antibody regdanvimab (also known ...
Posted by Michael Wonder on 24 Feb 2021
PHARMAC knew of epilepsy drug change risks within some patients, but went ahead with switch
24 February 2021 - PHARMAC knew there were clinical reasons some epilepsy patients would not tolerate a change to their medicines. ...
Posted by Michael Wonder on 24 Feb 2021
Antengene announces new drug application for ATG-010 (selinexor) granted priority review by China's NMPA
23 February 2021 - Antengene today announced that China's National Medical Products Administration has granted priority review to the new drug ...
Posted by Michael Wonder on 24 Feb 2021
Health Canada approves Dupixent (dupilumab) as the first biologic for the treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years
23 February 2021 - Dupixent is the only biologic medicine approved to treat atopic dermatitis for this patient population. ...
Posted by Michael Wonder on 24 Feb 2021
U.S. FDA accepts for priority review Pfizer's application for Ticovac (tick-borne encephalitis vaccine)
23 February 2021 - If approved, the vaccine may help reduce the risk of tick-borne encephalitis for people traveling to endemic ...
Posted by Michael Wonder on 24 Feb 2021
Inovise receives breakthrough device designation for novel non-invasive system to remotely monitor risk of decompensation in heart failure patients
23 February 2021 - Inovise Medical today announced the U.S. FDA has granted breakthrough device designation for its Audicor heart failure ...
Posted by Michael Wonder on 23 Feb 2021
TGA bans Pfizer, AstraZeneca brand mentions in COVID-19 vaccine advertising
24 February 2021 - Pharmacies, GPs and healthcare organisations will be banned from displaying advertisements identifying whether they are using ...